Zenlabs Ethica Ltd
₹
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd deals in marketing and distribution of pharmaceutical products.[1]
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Capital Turnover Ratio times ・Standalone data |
|
||||||||||
| Number of Permanent Employees number ・Standalone data |
|||||||||||
| Trade Receivables Turnover Ratio times ・Standalone data |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - CERTIFICATE UNDER REGULATION 74(5) OF THE SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS,2018 FOR THE QUARTER ENDED MARCH 31,2026.
-
Declaration Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011 ('SAST Regulations')
7 Apr - Promoter group confirms nil pledged or encumbered shares as of March 31, 2026.
- Closure of Trading Window 30 Mar
-
Announcement under Regulation 30 (LODR)-Change in Management
2 Mar - Amit Kumar resigned as Company Secretary & Compliance Officer effective 02 March 2026 (resignation dated 23 Feb 2026).
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
2 Mar - Amit Kumar resigned as Company Secretary & Compliance Officer effective March 2, 2026 (personal reasons).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
a) ZEL is a part of the Preet Remedies Group. It is a WHO–GMP certified contract manufacturing pharmaceutical firm which operates across manufacturing and distributing diversified pharmaceutical formulations under multiple divisions (Zenlabs, Coles Pharma, Mega Star), servicing both domestic and international markets including Southeast Asia.
b) The company does third party manufacturing for Preet Remedies Group which has 5 production units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, the minimum
order quantity offered is 2000 boxes
of drugs.
c) The company is also into private label manufacturing of different pharmaceutical products.